ZENECA ZOLADEX SALES UP 34% TO $195 MIL. IN FIRST HALF; ZESTRIL VOLUME GROWS 14%, REVENUES RISE 10% TO $379 MIL.: U.S. PHARMA CERVICAL SALES TOTAL $623 MIL.
Executive Summary
Zeneca's Zoladex sales climbed 34% to $195 mil. for the first half of 1995 with a sales volume increase of 33%, a price decrease of 2% and a 2% loss due to currency exchange fluctuations, the company reported at an Aug. 3 meeting with securities analysts in New York City
You may also be interested in...
Boston Scientific Pays More Than $1Bn For Lumenis’ Surgical Laser Business
Lumenis’ surgical business includes the MOSES laser system for minimally invasive urology surgery which will complement Boston Scientific’s LithoVue ureteroscope.
Finance Watch: Eleven Companies Reveal $1.45bn In $100m-Plus VC Deals
Private Company Edition: Clover’s $230m financing was the largest of recent mega-rounds. Century Therapeutics ($160m), Vividion ($135m) and eGenesis ($125m) also raised big rounds and investors Foresite Capital ($969m), Sofinnova Partners ($540m) and OMX Ventures ($150m) raised new VC funds.
Takeda Takes Back Dravet, Lennox-Gastaut Candidate From Ovid
Revising the two companies’ 2017 epilepsy collaboration, Takeda will take over Phase III development and commercialization of soticlestat. Ovid gets $196m up front, and it can shift focus.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: